No abstract

Immunotherapy has shown promising applications in cancer treatment as it boosts the systemic immune response. Existing immunotherapy strategies have certain drawbacks which can be addressed by engineered biomaterials. In this review, we focused on advanced immunotherapy methods involving implantable and injectable biomaterials for the treatment of cancer. Engineered biomaterials as carriers for immunomodulatory agents aid in the local drug delivery, thus reducing the frequency of off-target side effects. Also, biomaterial-based cancer vaccines have the potential to target specific tissues by finely altering the physical properties of the drug to achieve desired drug release kinetics.

The In-silico studies encourages design of the drug molecules, understanding and development of the pathways, protein-protein interactions, stability of the molecules etc. these studies also help in identifying the disorders and in turn to derive the new drug molecules. Galactosemia is one of the metabolic disorders that affect the metabolism of the sugar galactose. It leads to accumulation of the galactose in the blood leading to quite morbidity and genetic disorders.The current paper discuss about the interactions between the variants of Galactose-1 -phosphate uridylyltransferase (GALT).Using the Mutater software, the mutations N314D, S135L K285N and Q188R were incorporated in the sequence of the unmutated GALT.